跳至主要内容
临床试验/NL-OMON41902
NL-OMON41902已完成不适用

The effect of riboflavin supplementation on Faecalibacterium prausnitzii in Crohn's disease - Riboflavin in Crohn's disease / RISE-UP study

niversitair Medisch Centrum Groningen0 个研究点目标入组 84 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
84

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • Group 1 (n=42)
  • - Patients diagnosed with Crohn*s Disease in remission (Calprotectin < 200 µg/g)
  • - Age 18-65 years;Group 2 (n=42)
  • - Patients diagnosed with Crohn*s Disease with active disease (Calprotectin > 200 µg/g)
  • - Age 18-65 years

排除标准

  • - Swallowing disorders
  • - Pregnancy and lactation
  • - Use of antibiotic drugs, probiotics (i.e.Yakult, Vifit, Activia etc) or specific prebiotic supplements in the 3 weeks prior to the riboflavin intervention (for a list of probiotic, prebiotic and other supplements see attachment 2)
  • - Use of Methotrexate drugs.
  • - Colonoscopy and colon cleansing in last 3 months
  • - Use of a vitamin B2 supplement, or multivitamin complexes containing vitamin B (i.e. vitamin B-complex) in the 3 weeks prior to the riboflavin intervention
  • - Severe Crohn*s disease (HBI > 12)

研究者

相似试验